Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics announced four presentations, including two late-breaking clinical research talks, at the HFSA Annual Scientific Meeting 2026 in Phoenix from October 9-12. The late-breaking talks cover global efficacy and exercise performance results of aficamten in non-obstructive HCM from the Phase 3 ACACIA-HCM trial; two additional orals cover SEQUOIA-HCM right ventricular function and ACACIA-HCM dosing and safety data.
Key figures
- Drug Name
- aficamten (MYQORZO)
- Guidance
- Plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026
- Phase Of Trial
- Phase 3
- Presentation count
- 4
- Late breaking count
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.